Ian Walters

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Philip J. Johnson, Shukui Qin, Joong‐Won Park et al. · Journal of Clinical Oncology · 2013 · 775 citations · Full text

Medicine, Oncology, Pharmacology +14

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul et al. · Journal of Clinical Oncology · 2013 · 596 citations · Full text

Medicine, Oncology, Pharmacology +13

The Majority of Epidermal T Cells in Psoriasis Vulgaris Lesions can Produce Type 1 Cytokines, Interferon-γ, Interleukin-2, and Tumor Necrosis Factor-α, Defining TC1 (Cytotoxic T Lymphocyte) and TH1 Effector Populations:1 a Type 1 Differentiation Bias is also Measured in Circulating Blood T Cells in Psoriatic Patients

Lisa M. Austin, Maki Ozawa, Toyoko Kikuchi et al. · Journal of Investigative Dermatology · 1999 · 483 citations · Full text

Medicine, Dermatology, Immunology +17

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

Masatoshi Kudo, Guohong Han, Richard S. Finn et al. · Hepatology · 2014 · 347 citations

Pharmacy, Oncology, Pharmacology +14

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

Riccardo Lencioni, Robert Montal, Ferràn Torres et al. · Journal of Hepatology · 2017 · 227 citations · Full text

Medicine, Oncology, Survival Analysis +12